Pioneering rational design of drugs made of defined bacteria consortia that are essential dwellers of the gut ecosystem. The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Harnessing the microbiome for the development of diagnosis and therapeutic tools in cancer ! EverImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology. It harnesses the gut microbiota for the development of a unique approach aiming to restore the response of Immune Checkpoint Inhibitors (ICIs) in cancer patients. The company is developing Oncobax AK, a Live Biotherapeutic Product (LBP) used as an oral adjuvant to anticancer immunotherapies, designed to safely boost the immune system and restore sensitivity to immunotherapies in primary resistance settings. The company also develops other bacteria in …

123 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing mRNA vaccines and therapeutics In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company. This acquisition further accelerates Sanofi’s efforts to develop transformative vaccines and therapies using mRNA technology. It adds a critical pillar to the company’s mRNA Center of Excellence, which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We …

144 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiome field. Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiota field. Our mission is to discover, develop and bring to market safe and novel therapeutic options, preserving patients’ microbiota to prevent and cure life-threatening diseases. We strive to serve patients by transforming the promise of science into innovative treatments which have the power to improve health and save lives.​ Committed to innovation, Da Volterra develops products intended to protect the intestinal …

89 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. pharmaceutical development

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Diotheris develops anti-infective microbes to prevent bacterial infections and act against antibiotic resistance We create bacterial therapies of the human skin and mucosal microbiome against pathogenic bacteria. Our first suite of products (NASOFLORE line) targets Staphyloccocus aureus / MRSA (Methicillin resistant S aureus). The products based on live bacteria identified in our clinical and in vitro studies do not generate emergence of antibiotic resistance. antimicrobial, nose microbiome, therapeutics, LBP, Staphylococcus Aureus, and MRSA

71 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Leading the Microbiome revolution Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWSTTM, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in …

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

For every therapeutic challenge, we question traditional assumptions and find better solutions. VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by autoimmune diseases. The catalyst of the company’s differentiated approach is its proprietary InhiBETTM Platform that potentially unlocks a promising new drug target for improving the treatment of challenging I&I diseases with …

90 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Why replace antibiotics when we can make them work better? AI matches the bacterial genome to an adjunct - Phages first Why replace antibiotics when we can make them work better? Resistance often doesn't mean an antibiotic is finished — it means it needs a partner. We are the AI infrastructure layer that finds that partner in minutes, not months - starting with phages. Our platform reads the bacterial genome of a resistant isolate and returns the adjunct most likely to restore the antibiotic's response — ranked, scored, and confirmed by the ordering laboratory before any clinical use. Minutes, not …

81 similar entities Type: Startup Activities: deeptech healthtech Technologies: A.I.

Redefining microbiome-based therapeutics MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.The company is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent, Belgium, and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB and has a corporate collaboration with DuPont Nutrition …

129 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche …

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vital new drugs for pandemic infections We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections. Pharmaceuticals, R&D, Antimicrobial Resistance, and Development

147 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

ProteinLogic has developed a novel technology platform (ImmiPrint®) focused on the diagnosis of tuberculosis (TB). Along with HIV/AIDS, TB is the most significant infectious disease worldwide. Early and accurate diagnosis is essential for its control. The ImmiPrint® platform has the potential to deliver an effective blood-based TB diagnostic, and to provide information on disease progression. The test may also be able to predict which individuals are likely to respond to anti-microbial therapy.

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leadership in overcoming the antibiotic resistance crisis. BioVersys AG is a SIX listed (BIOV) clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s two in house technology platforms: i) TRIC and ii)Ansamycin chemistry, BioVersys develops novel, innovative antibacterial drugs, overcoming resistance and modulating the microbiome. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Therapeutic Innovations and Resistance INTHERES research revolves around the exploration of dose-exposure-effect relationships of antibiotics and internal and external antiparasitics. Their aim is to produce innovative solutions that lead to reduced and optimized use of anti-infectives. The work carried out within INTHERES is part of a “One-health” approach, at the interfaces of the Man-Animal-Environment triptych. INTHERES is a multidisciplinary unit, whose collective brings together skills in the fields of biology (microbiology, entomology, parasitology, cellular and molecular biology), analytical chemistry, pharmacology and mathematics. INTHERES welcomes university hospital staff (Faculty of Pharmacy), in conjunction with the Toulouse University Hospital. They are developing …

64 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

We produce customised chemical proteins to help our bio-pharms partners to accelerate their projects. 🧪 X’PROCHEM is a biotech company who invented an advanced and proprietary ligation technology. We help our bio-pharma partners design and create therapeutic, vaccine and diagnostic proteins. Unlike recombinant fermentation we can produce proteins containing up to 400 amino acids, without isoforms, endotoxins, or biological contaminants. We co develop solutions with our partners to understand the real needs within the context. By working closely, we can adapt to changing needs and circumstances. protein, purification, synthesis, protein production, peptide synthesis, and life sciences

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Protecting immunocompromised patients from severe viral infections SpikImm has been founded by Truffle Capital and Institut Pasteur. SpikImm’s unique mission is to develop prophylactic mAbs against severe viral diseases in immunocompromised patients. First product is a potent anti-BK virus mAb to protect kidney transplant patients from severe complications caused by BKV, including nephropathies that may result in graft loss.

59 similar entities Type: Startup Activities: deeptech healthtech

Make Visible the Invisible Faster to Make your World Safer Founded in 2014, DIAMIDEX (Diagnostic Microbiology Express) is an innovative company specialized in the detection and quantification of microorganisms of interest. Its mission: making the invisible visible faster, to make your world safer. Its patented innovative technological approach brings about a major breakthrough to meet the speed and technicality challenges arising from microbiological culture. Based on a powerful technological platform, recognized by the scientific and industrial communities, DIAMIDEX offers and develops turnkey test solutions, which can be used in both laboratories and in the field to obtain a quantitative count …

136 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

goes FAR BEYOND (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases) Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed. Dimicare Biotech is building a great team involving Microbiology Medical doctors, …

171 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting iRhom2 for better treatment of autoimmune diseases SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases. drug …

88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developpment of small molecules to prolong the protective effect of the Integrated Stress Response InFlectis BioScience is a private clinical-stage company aiming to target and modulate interactions between proteins involved in key human pathophysiological processes. The company is developing IFB-088 (INN: icerguastat), which specifically targets the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of diseases affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation. …

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Focusing on Resistance in Antibiotic Development Qpex Biopharma, Inc. a Shionogi Group Company, is a resistance-focused infectious disease company on a mission to make both a dramatic and sustainable improvement in patient care. Leveraging a multi-faceted approach and a deep understanding of drug resistance mechanisms, we are creating novel products and development. strategies that overcome multi-drug resistance. We are advancing a robust portfolio of treatments that will bring innovation to antibiotic development and deliver the right treatments to the right patients in the right settings. During the previous decade, our team brought 4 antibiotic products to regulatory approvals, with an …

79 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Evolution. Adaptation. Future. Phage-based solutions to combat bacteria. - Prevention - Diagnosis - Treatment "One Health" personalized treatments. biotecnología, microbiología, investigación, biomedicina, bacteria, phage, and phage therapy

185 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Bioceltix is changing the veterinary therapy standards. We develop innovative biopharmaceuticals based on stem cells. Bioceltix is a Wrocław-based and internationally oriented biotechnological company developing innovative, both stem cells and secretome based products, for companion animals. Our flagship technology for manufacturing biopharmaceuticals for veterinary use utilizes the therapeutic potential of allogeneic stem cells (one donor – many recipients). Owning a GMP production facility, we provide single technology for several species, diseases, and routes of administration. Our cutting-edge approach will allow the product to be batch-produced and ready for off-the-shelf sale. The veterinary medicines, based on the immunomodulatory mechanism of action …

231 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Saving lives through affordable and efficient bacterial vaccines Gefjon Pharma has developed a groundbreaking platform technology based on our unique hyper vesiculating outer membrane vesicle (OMV) technology. This combined with our unique extraction method enable high-yield cost-effective production of bio-industrials and therapeutics. Our first product is a revolutionary broad-protective bacterial E. coli vaccine targeting poultry production. We have PoC for both the vaccine and an aerosol application method. With E. coli being the single most important cause of mortality and infections in poultry, we will significantly reduce global consumption of antimicrobials, thereby minimizing the development of antimicrobial resistance (AMR), improve …

89 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Developing a novel antibiotic regimen with ability to act on a wide range of multi-drug resistant bacteria. Thioredoxin Systems AB is a biotechnology company developing a novel antibiotic regimen against pathogenic bacteria. EbsArgent is a patented combination of ebselen and silver, capable of functioning as an antiseptic, antibacterial in food production, and as a medicinal product. With its versatility and ability to act on a wide range of multi-drug resistant bacteria, it is among the most promising antibiotic regimen under development today.

68 similar entities Type: SMB Activities: biotech healthtech deeptech Technologies: Synthetic Biology

Vaccines against antibiotic-resistant infections Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators in the development of multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Our vaccines target high-risk populations, population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates. We are strongly committed to contribute to reducing antibiotic use in the world by following a One-Health approach. Vaxdyn is the first Spanish biotech funded by CARB-X. CARB-X awarded Vaxdyn …

76 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering A New Class of Universal Vaccines Osivax is a clinical-stage biopharmaceutical company developing a portfolio of differentiated influenza vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses, thanks to its novel, self-assembling nanoparticle platform technology, oligoDOMTM. The company’s lead candidate, OVX836, is a broad-spectrum influenza A vaccine candidate currently in Phase 2b clinical trials with over 4,000 volunteers tested and encouraging efficacy proof of concept data. By combining OVX836 with standard flu vaccines, Osivax is advancing toward a best-in-class seasonal flu vaccine to prevent all strains of influenza. Osivax collaborates with leading global health agencies …

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Molecular biology thought for your needs Biomnigene, a bioanalysis service company, helps prevent potential diseases and to authenticate, trace, secure, validate products and their effects through genetic analysis. Thanks to our expertise, we offer you integrated services for environmental, industrial (pharmaceutical, agro-food, cosmetic) or medical issues such as: - Analysis of the intestinal, skin, vaginal, pulmonary and soil microbiome (16S/ITS metagenomic, shotgun metagenomic, transcriptomic, WGS...). - Identification, quantification and authentication, monitoring of species in a pure sample and in a mixture (microorganisms, viruses, bacteria, meat, fish). - Genotyping - Antibody sequencing and safeguarding of hybridoma lines of special interest; - …

197 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crossing the next frontier, to give you a fair chance to fight Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms. Inflammatory Bowel Diseases, Live Biotherapeutics, Microbiome, Immunotherapies, Immuno-oncology, and Immuno-inflammation

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Fabentech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields …

106 similar entities Type: Startup Activities: biotech deeptech healthtech manufacturing Technologies: Synthetic Biology

Texcell is a viral safety expert with roots dating back to 1987. Our work sits where science meets urgency. About Texcell We are a specialized CRO supporting biologics, vaccines, medical devices, cell and gene therapies, and other complex biological products. Our core expertise includes viral safety, viral clearance, biosafety testing, custom cell culture, cell banking support, and bioassays. For more than 30 years, clients have trusted Texcell for scientific rigor, responsive partnership, and practical support when programs need clarity. We design studies, solve technical questions, assess product safety, and move development programs forward with confidence. Our services include: Viral safety …

94 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A nature-inspired solution to trap pathogens @AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the @Région Auvergne-Rhône-Alpes, France, incorporated in March 2023 with the objective of developing a new class of sugar-based anti-infective biotherapeutics to fight (re)emerging infectious diseases. Thanks to a Bioengineering plateform based on the expertise of the leading edge academic laboratory @CERMAV (@CNRS, @UGA, Grenoble, France), AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat infections by mimicking the natural host surface oligosaccharide binding-sites of pathogens. GlycoFlu, our first drug-candidate validated at the …

80 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The box that takes care of you. French drug laboratory 🇫🇷 Biogaran, a French pharmaceutical laboratory founded in 1996, is the pioneer of generic medicines in France. For nearly 30 years, we have contributed to the sustainability of the health system and access to care for all. With more than 1,000 drug references and services designed to promote compliance, we play a key role in the health of the French people. Always on the move, Biogaran innovates and reinvents itself to meet the needs of each patient. Beyond generics, we develop biosimilar medicines, solutions for everyday ailments and wound care, …

123 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

At the forefront of the fight against antibioresistant bacteria Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human cells. Antimicrobial resistant bacteria or AMR are responsible for over 700,000 death a year in 2014 according to the WHO. This number might reach over 10,000,000 by 2050 if nothing is done, and no new class of antibiotics has been discovered in the last 30 years. Phages represent one of …

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

hVIVO - Making Innovation Possible Venn Life Sciences is now hVIVO. Making Innovation Possible hVIVO plc (Ticker: HVO) is a science‐led early‐phase drug development company purpose‐built to meet the growing complexity of modern clinical research. The Company operates an integrated early‐phase ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision‐ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials. With industry‐leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other …

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in …

270 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. Anti-Infectives, Drug Discovery, Antibiotics, and Microbiology

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

For the benefit of patients Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in the heart of the life sciences hub of Basel area, Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea currently has about 150 employees and is listed on the SIX Swiss Exchange (SIX: …

98 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

we develop for patients Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university …

85 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Some things cannot be comprised especially quality of life saving drugs, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That`s why, we at Inven, are committed to apply science and our resources, for providing most innovative and quality products. We strive to provide access to safe, effective and affordable medicines to the people who need them. With a strong research oriented work culture, state-of-the-art production facility and end-to-end product development capabilities - Inven is recognized as a leading, ISO 9001-2000 and WHO GMP certified, IV fluid manufacturer in the international and domestic …

136 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

rethinking microbiome Mikrobiomik is a biopharmaceutical company created for the research and development of therapies based on the human microbiome. Our Mission At Mikrobiomik we develop innovative therapies based on intestinal microbiota to offer new therapeutic options in serious diseases with unmet medical needs. Through our FSPIM® technology, we work to restore the balance of the microbiome and provide healthcare professionals and patients with safe, standardized and accessible therapeutic solutions in clinical practice. Fecal microbiota transplant (FMT)

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are …

370 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Phico Therapeutics is a biotechnology company advancing the war on antibiotic resistance with engineered phage therapy. At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”. Our patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. With a number of advantages over conventional antibiotic classes, SASPjectTM could form the basis for a new generation of antibiotics to overcome antimicrobial resistance. Watch our animation to discover how our technology works: https://www.youtube.com/channel/UCjPndK0F9ufmEy9fBQFTsUg Twitter: @Phicotx …

65 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Reinventing Cancer Immunotherapy Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea …

188 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

a wholly owned subsidiary of Eli Lilly and Company LimmaTech Biologics AG, a wholly owned subsidiary of Eli Lilly and Company, is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. vaccines, research & development, biotechnology, and antimicrobial resistance

419 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Une entreprise spécialisée dans le développement de thérapies transformatrices ayant un impact sur la longévité. Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally: • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with sarcopenia, …

263 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovative therapeutic procedures for Intensive Care Medicine for the treatment of severe infections / sepsis ARTCLINE GmbH develops innovative therapy methods for intensive care medicine based on immune cells. Our current main project is the development of the so-called ARTICE technology for the treatment of bacterial sepsis. ARTCLINE's vision is the development of innovative immune cell-based therapy approaches and to make the technology available to physicians and hospitals worldwide. The safety and effectiveness of the therapy is our top priority. Our extensive cell biological, clinical and industrial experience in the fields of immunology, sepsis diagnostics and therapy help us to …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders

148 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids

346 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering the development of microbiome-based therapies using proprietary tools for their design and production. PharmaBiome is a privately-held spin-off company of ETH Zurich and a pioneer in the production of live biotherapeutic products to address disturbances of the gut microbiome. It has developed the first-in-the-industry, patent-protected technology platform for the production of standardized microbiome-based products. Founded in Zurich in 2015, at the intersection of microbiology, biotechnology, and data science, PharmaBiome believes that the future of microbiome-based therapeutics lies in developing the biotechnology needed to produce a solution compatible with the safety, efficiency, and trial requirements of any human medicine. This …

92 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class solutions for unmet health and personal care needs Results through innovation. We are an innovative biotechnology group with two divisions. Our consumer health arm has commercial products for the personal care market addressing nail, skin, scalp and hair issues. NovaBiotics pharma division has advanced clinical-stage product candidates for medically unmet, life-limiting inflammatory, infectious and respiratory disease. Our highly disruptive solutions to personal care and health needs address significant global markets. biotechnology, biologics, infectious disease, and drug discovery & development

225 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

147 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovating vaccines to reduce human diseases. Part of Utrecht Science Park Bilthoven Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies. As an established independent CDMO in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials …

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biopredic International is committed to support Life Science Research by developing and distributing biological tools. We assist both academia and industries in drug development, drug discovery, cosmetic and chemical fields. Biopredic International delivers assays, tissues, cells and reagents including: > High quality hepatocytes (human and animal, fresh or cryopreserved) and other liver-derived products (microsomes, S9 fractions and cytosols) > Skin products (fresh or frozen), including human skin discs and skin sheets (full thickness, dermatomed, stratum corneum), skin cells (keratinocytes, fibroblasts), subcellular fractions... > Blood products, including whole blood, sera, plasma, PBMCs, lymphocytes, monocytes, dendritic cells, CD34... > And other products …

97 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

A Sundew company We are creating a potentially revolutionary algal platform technology. Thanks to major advances in algal genomics and molecular biology, microalgae can be engineered to express inexpensive therapeutic proteins and vaccines of economic value. The cost of the synthetic biology tools has dropped. We are building our technology based on solid, peer-reviewed science[1][2][3][4]. By using microalgae as an oral delivery vehicle, we can substantially cut the labor and post-processing production costs, allowing us to produce effective vaccines that are much more affordable and user-friendly. Our technology can reduce or eliminate the use of antibiotics, reduce fish mortality rates …

89 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Discovering & developing novel anti-infectives to treat multi-drug resistant bacterial & hard-to-treat viral infections. Venatorx Pharmaceuticals is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. antibiotics, antiinfectives, antivirals, drug development, drug discovery, pharmaceuticals, #battlesuperbugs, #WorkingToFightAMR, clinical, research, #squashsuperbugs, biotech, and antimicrobialresistance

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating research & development Integrated BioTherapeutics LLC (IBT Bioservices) is a contract research organization (CRO) offering in vitro and in vivo services as well as products to support your biomedical research and development needs. Whether you are a biotech startup or an established pharmaceutical company, IBT serves as your trusted partner, simplifying the development process and accelerating your journey toward bringing innovative biotherapeutics to patients in need. The team of highly skilled scientists, researchers, and industry experts at IBT work collaboratively to deliver exceptional results and accelerate the development process for its clients. By offering comprehensive services and concierge-level support …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Bioharmony Therapeutics, we are developing nontraditional antimicrobial therapeutics by exploiting millions of years of phage-bacteria evolution. Our focus is on targeting infectious diseases caused by multidrug-resistant (MDR) Gram-negative bacteria. Our primary therapeutic indication is for Acinetobacter baumannii skin and wound infections.

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Framing the future of autoimmune diseases Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Formulating the Future of BiologicsTM Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, HyperconTM, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are …

276 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology